Banu Arun: Pioneering New Horizons in BRCA-Positive Breast Cancer Treatment
Join Dr. Banu Arun from MD Anderson Cancer Center at the 17th Breast, Gynecological and Immuno-oncology International Cancer Conference in Cairo, where she will present groundbreaking data on combining PARP inhibitors with immune checkpoint inhibitors—a promising strategy for targeting BRCA-mutated tumors.
This highly anticipated session will explore novel combination therapies that could transform
the treatment landscape for BRCA-positive breast cancer and improve patient
outcomes.
- Event Dates: January 23-24, 2025
- Hilton Heliopolis Hotel, Cairo, Egypt
- Register today.
Other posts featuring BGICC.
Dr. Banu Arun is a Professor in the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center and Co-Medical Director of the Clinical Cancer Genetics Program. She serves as Co-Chair of the Prevention and Epidemiology Committee for the SWOG Cancer Research Network and is a member of the ASCO BOLD Task Force and NCCN Breast Cancer Risk Assessment Committee. Her research focuses on breast cancer treatment, biomarkers, chemoprevention, and genetics. Dr. Arun has led phase II prevention trials with agents such as celecoxib, atorvastatin, and targretin, as well as clinical trials exploring PARP inhibitors in breast cancer. She also investigates risk factors and tumor biology in high-risk women, including those with BRCA1 or BRCA2 mutations.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023